Daily Newsletter

14 November 2023

Daily Newsletter

14 November 2023

Victoria Atkins MP takes over UK’s department of Health and Social Care

The UK government has seen a cabinet reshuffle as the Prime Minister removed Steve Barclay as UK health secretary and replaced him with newcomer, Victoria Atkins.

Joshua Silverwood November 13 2023

The UK Prime Minister, Rishi Sunak, has confirmed that Victoria Atkins has been appointed Secretary of State for Health and Social Care amid a cabinet shake-up.

The Conservative MP for Louth & Horncastle was appointed to the position today (13 November) during a cabinet reshuffle that saw the previous incumbent, Steve Barclay, removed from his position.

From 2017 to 2021 Victoria Atkins was the Parliamentary Under Secretary of State for Crime, Safeguarding and Vulnerability at the Home Office, and then moved on to become Financial Secretary to the Treasury between 27 October and 13 November 2022.

Initially a barrister by trade and with no formal background in the healthcare trade, her husband Paul Kenward is Managing Director of British Sugar, a firm licensed to grow cannabis for use in children’s epilepsy medication.

Now, Atkins will have to helm the government department as it navigates a winter of disruption and potential strikes ahead of the Christmas period.

Steve Barclay has now moved on to take over the position of Secretary of State for the Environment, Food and Rural Affairs (DEFRA).

The cabinet reshuffle also comes after a landmark decision in the UK courts that saw a critically ill baby at a Nottingham Hospital have his life-support device switched off after the hospital ruled there was nothing more it could do.

This event and its legal ramifications are expected to take up a significant portion of Atkins’ attention from the start of her tenure.

A spokesperson for Nottingham University Hospital Trust said: “We are all deeply saddened by the death of Indi and wish to express our heartfelt condolences to her family at this terribly difficult time. 

“This has been a very long and challenging journey for Indi, her parents and everyone involved, and we will all be holding them in our thoughts.”

Disease-modifying therapies (DMTs) entering the PD market pose significant opportunities and risks

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs. However, the lack of validated predictive biomarkers of PD progression have made the development of DMTs and neuroprotective agents challenging.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close